Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients
Open Access
- 23 November 2017
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 34 (11) , 859-868
Abstract
Management of elderly inflammatory bowel disease (IBD) patients (≥ 65 years of age) is complicated due to many factors, including a higher risk of cancer, which may impact therapeutic decisions.Keywords
This publication has 24 references indexed in Scilit:
- Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based StudyAmerican Journal of Gastroenterology, 2016
- Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort studyBMJ Open, 2015
- Biologic agents for IBD: practical insightsNature Reviews Gastroenterology & Hepatology, 2015
- Next-Generation Therapeutics for IBDCurrent Gastroenterology Reports, 2015
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel DiseaseJAMA, 2014
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's DiseaseGastroenterology, 2014
- Systematic review with meta‐analysis: inflammatory bowel disease in the elderlyAlimentary Pharmacology & Therapeutics, 2014
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeAmerican Journal of Gastroenterology, 2010
- Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2009
- Polypharmacy in elderly patientsThe American Journal of Geriatric Pharmacotherapy, 2007